Cannabidiol Attenuates Doxorubicin-Related Cardiac Disorders Using Modulation of IL6R Signifying Trail in Adult Male Sprague Dawley Rats

Chemotherapeutic medications are commonly used for treating a variety of cancer types; nevertheless, they can also have biological adverse effects, particularly on non-tumor cells, and regularly upset the physiological balance in a number of different organs, specifically the heart. The current inquiry's objective was to determine how well Cannabidiol (CBD) oil mitigated the cardiotoxicity caused by Doxorubicin (DOX). Five equal groups of fifty male Sprague-Dawley rats with 150±25g were molded. Group I received distilled water orally, while Group II received an intraperitoneal dose of DOX (18 mg/kg bwt). CBD was given to Group III, while 1 ml CBD (26 mg/kg bwt) was given to Group IV, and Trimetazidine (10 mg/kg bwt) was given to Group V. Both groups (IV and V) also got a single dose of Doxorubicin (18 mg/kg bwt) on the 11th day. Heart histology, biochemical measurements, immunological tests, and gene expression were examined. In addition to bringing ECG and blood pressure back to normal, the administration of CBD (26 mg/kg bwt) showed a substantial improvement in cardiac enzyme activity (Troponin I and CK-MB), and is related to decreasing cholesterol and triglycerides. Additionally, there was a reduction in oxidative stress, as measured by MDA, and inflammatory markers (IL6 and TNF-a) and improvement in SOD, GSH in cardiac homogenate. There has also been a noticeable drop in the expression of the frequency concentration of IL6R associated with improved heart tissue. CBD may be protective because of its anti-inflammatory and antioxidant assets.